Patient and Provider Perceptions Surrounding Affordability for HF Treatments
Experts share their thoughts on payer and provider perceptions surrounding affordable HF care, as well as strategies to manage care-associated costs.
Navigating Multidisciplinary HF Treatment With Multiple Comorbidities
Multiple comorbidities lead to an emphasis on multidisciplinary care management when determining the most effective HF treatment strategies.
Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Gaining Confidence With a Switching Study
Sonia T. Oskouei, PharmD, BCMAS, DPLA, navigates the impact of the VOLTAIRE-X study, the only published switching study for adalimumab, on biosimilar uptake.
Treatment Landscape Surrounding Anti-Fibrotic Agents
Dr Noble, MD provides and overview of the treatment landscape surrounding ILD, specifically examining IPF, PPF, and SSc-ILD antifibrotic therapy.
ATS Guideline Updates in Treatment Paradigms for ILD
Dr Paul Noble, MD discusses updates and changes in ATS-directed guidelines for the treatment of ILD.
The Role of MRAs in CKD and CV Treatment
Dr Agarwal provides a deep dive into the use of nonsteroidal mineralocorticoid receptor antagonists in CKD therapy.
Treating CKD Using Multiple Methods
Dr Feldman concludes the treatment landscape overview by discussing glycemic control, SGLT2 inhibitors, and other important management techniques.
IMpower010 Trial Evaluating Atezolizumab Versus Best Supportive Care (BSC)
Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).
Future Opportunities to Improve PrEP Access and Management
Carl Schmid and Lynne H. Milgram, MD, MBA, CPE, conclude with sharing ideas that can provide more substantial access to PrEP and battle unmet needs in PrEP management.
Enhancing Patient Education on PrEP Therapies
Drs Palella Jr and Milgram explains the disconnect between PrEP and patient education and comments on how to fix it.
The Social Determinants Affecting PrEP Use and Access
Carl Schmid and Dr Milgram discusses the disparities in education and access to PrEP in the patient populations that need these medications the most.
Improving HF Population Health Management and Collaborative Care
Dr Uppal outlines population health management strategies directed to improve access to care and treatment management for patients with heart failure.
Cost-Saving Strategies Through PCP-Prescribed Therapies in HF
Dr Murillo navigates cost-saving strategies for heart failure treatment by emphasizing collaborative care between specialists and frontline primacy care teams.
Aligning Payer and Provider Considerations
Navigating payer and provider considerations to ensure optimal care management for vitiligo.
Optimal Therapies for Treating Vitiligo
A variety of treatment options for vitiligo are explored by Drs Dunn, Rosmarin, and King.
Blood Pressure Management Within the CKD Treatment Landscape
Drs Agarwal and Pitt begin an overview of the CKD treatment landscape, beginning with the importance of blood pressure management.
Treatment Goals for Patients With CKD
Jeffrey Feldman, MD, describes the treatment goals for patients with CKD.
Receiving Grade A Recommendations for Injectable PrEP and New Agents
Lynne H. Milgram, MD, MBA, CPE, speaks about the USPSTF Grade A recommendation for injectable cabotegravir and how it could affect emerging agents in the future.
Utilizing Data for Policies and Cost-Effectiveness of PrEP Agents
Dr Milgram focuses on the cost-effectiveness of cabotegravir as a long-acting injectable PrEP therapy and how providers and payers use data and real-world evidence to create PrEP policies.
SGLT2 Inhibitor Impact on Hospitalization Reduction and HF Disease Progression
The impact of SGLT2 inhibitors in heart failure treatment is highlighted by the EMPEROR-Preserved and EMPEROR-Reduced trials.
Balancing Payer Utilization Strategies With Clinical Effectiveness in HF
Jaime Murillo, MD, outlines payer utilization management strategies identified by the PARADIGM-HF study.
Vitiligo Diagnosis Determining Treatment Pathways
Key opinion leaders discuss how diagnosing vitiligo can lead to myriad treatment options.
Economic Burden Surrounding Vitiligo
The panel of experts address the economic burden of vitiligo from payer and provider perspectives.
Preventing CKD Underdiagnosis
Paul Sapia, MHA, acknowledges the underdiagnosis in CKD and explains how payers can incentivize screening going forward.
Screening for CKD
Dr Rajiv Agarwal explains the screening process for patients with CKD, including those who are asymptomatic.
Switching to Appropriate Guideline-Directed Therapy to Improve HF Patient Outcomes
Experts discuss improving outcomes for patients with heart failure through appropriate and timely switches to ARN inhibitors.
Pivotal Clinical Trials Shaping HF Treatment Landscape
The panel explores clinical evaluations, such as the PROVE-HF study and PARADIGM-HF trial.
Knowing the Ins and Outs of Injectable PrEP
Frank J. Palella Jr, MD, and Carl Schmid continue the discussion of patient selection for long-acting injectable PrEP and its cost effectiveness in comparison with other PrEP modalities.
Identifying the Right Patient for Injectable PrEP
Dr Lynne H. Milgram starts the conversation on choosing the right candidate for long-acting injectable PrEP, as well as how findings show it is cost effective.
